Literature DB >> 16304176

Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli.

Sara K Olofsson1, Patricia Geli, Dan I Andersson, Otto Cars.   

Abstract

Antibiotic dosing regimens may vary in their capacity to select mutants. Our hypothesis was that selection of a more resistant bacterial subpopulation would increase with the time within a selective window (SW), i.e., when drug concentrations fall between the MICs of two strains. An in vitro kinetic model was used to study the selection of two Escherichia coli strains with different susceptibilities to cefotaxime. The bacterial mixtures were exposed to cefotaxime for 24 h and SWs of 1, 2, 4, 8, and 12 h. A mathematical model was developed that described the selection of preexisting and newborn mutants and the post-MIC effect (PME) as functions of pharmacokinetic parameters. Our main conclusions were as follows: (i) the selection between preexisting mutants increased with the time within the SW; (ii) the emergence and selection of newborn mutants increased with the time within the SW (with a short time, only 4% of the preexisting mutants were replaced by newborn mutants, compared to the longest times, where 100% were replaced); and (iii) PME increased with the area under the concentration-time curve (AUC) and was slightly more pronounced with a long elimination half-life (T(1/2)) than with a short T(1/2) situation, when AUC is fixed. We showed that, in a dynamic competition between strains with different levels of resistance, the appearance of newborn high-level resistant mutants from the parental strains and the PME can strongly affect the outcome of the selection and that pharmacodynamic models can be used to predict the outcome of resistance development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304176      PMCID: PMC1315921          DOI: 10.1128/AAC.49.12.5081-5091.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs.

Authors:  Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Journal:  Int J Antimicrob Agents       Date:  2002-04       Impact factor: 5.283

2.  Concentration-dependent selection of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistance.

Authors:  M C Negri; M Lipsitch; J Blázquez; B R Levin; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

3.  Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.

Authors:  Nelson Jumbe; Arnold Louie; Robert Leary; Weiguo Liu; Mark R Deziel; Vincent H Tam; Reetu Bachhawat; Christopher Freeman; James B Kahn; Karen Bush; Michael N Dudley; Michael H Miller; George L Drusano
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

4.  Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infection.

Authors:  Charles R Bonapace; Lawrence V Friedrich; John A Bosso; Roger L White
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

5.  In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.

Authors:  Alexander A Firsov; Sergey N Vostrov; Irene Y Lubenko; Karl Drlica; Yury A Portnoy; Stephen H Zinner
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

6.  Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection.

Authors:  Carole J Boylan; Kristina Campanale; Philip W Iversen; Diane L Phillips; Michael L Zeckel; Thomas R Parr
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

7.  Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.

Authors:  A Louie; P Kaw; W Liu; N Jumbe; M H Miller; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 8.  Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.

Authors:  Aamer Ali Shah; Fariha Hasan; Safia Ahmed; Abdul Hameed
Journal:  Res Microbiol       Date:  2004 Jul-Aug       Impact factor: 3.992

9.  Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections.

Authors:  Patricia Komp Lindgren; Asa Karlsson; Diarmaid Hughes
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model.

Authors:  Inga Odenholt; Ingegerd Gustafsson; Elisabeth Löwdin; Otto Cars
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

View more
  12 in total

1.  On the rapidity of antibiotic resistance evolution facilitated by a concentration gradient.

Authors:  Rutger Hermsen; J Barrett Deris; Terence Hwa
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-18       Impact factor: 11.205

2.  Modeling the mechanism of postantibiotic effect and determining implications for dosing regimens.

Authors:  Patricia Geli
Journal:  J Math Biol       Date:  2009-02-03       Impact factor: 2.259

Review 3.  Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance.

Authors:  Chiara Adembri; Andrea Novelli
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections.

Authors:  Peter Ankomah; Bruce R Levin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

5.  Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases.

Authors:  K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern
Journal:  Infection       Date:  2016-06       Impact factor: 3.553

6.  In vitro pharmacokinetic and pharmacodynamic evaluation of S-013420 against Haemophilus influenzae and Streptococcus pneumoniae.

Authors:  Tomoyuki Homma; Toshihiko Hori; Merime Ohshiro; Hideki Maki; Yoshinori Yamano; Jingoro Shimada; Shogo Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

7.  Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.

Authors:  Lorna E T Stearne; Wil H F Goessens; Johan W Mouton; Inge C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

8.  "One-size-fits-all"? Optimizing treatment duration for bacterial infections.

Authors:  Patricia Geli; Ramanan Laxminarayan; Michael Dunne; David L Smith
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

Review 9.  Emergence and spread of antibiotic resistance: setting a parameter space.

Authors:  José Luis Martínez; Fernando Baquero
Journal:  Ups J Med Sci       Date:  2014-03-30       Impact factor: 2.384

10.  Exposure to phages has little impact on the evolution of bacterial antibiotic resistance on drug concentration gradients.

Authors:  Quan-Guo Zhang
Journal:  Evol Appl       Date:  2014-01-02       Impact factor: 5.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.